Charles River Laboratories International, Inc. CRL
292.84
(1.60)
(0.54%)
as of 25 Sep
- Market cap
- $14.1B
- P/E
- 0.0×
Follow CRL
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years,
Insider Buys
alert about insiders buying in the last 12 month
Charles River Laboratories International, Inc. (CRL) Revenue
Charles River Laboratories International, Inc.'s revenue for fiscal 2025 was $4.0B, unchanged from fiscal 2024. Over the twelve months to 30 June 2026 it was $4.0B. Over the past ten years it has ranged from $1.4B (fiscal 2015) to $4.1B (fiscal 2023); the current reading is higher than 82% of that period. Charles River Laboratories International, Inc. ranks 12th of 50 Diagnostics & Research companies by revenue.
Revenue, annual
Annual
| Period | Revenue | Change |
|---|---|---|
| FY2025 | $4.0B | (0.85%) |
| FY2024 | $4.0B | (1.92%) |
| FY2023 | $4.1B | 3.86% |
| FY2022 | $4.0B | 12.31% |
| FY2021 | $3.5B | 21.08% |
| FY2020 | $2.9B | 11.55% |
| FY2019 | $2.6B | 15.67% |
| FY2018 | $2.3B | 21.99% |
| FY2017 | $1.9B | 10.48% |
| FY2016 | $1.7B | 23.34% |
Quarterly
| Period | Revenue | Change |
|---|---|---|
| Jun 2026 | $1.0B | 0.83% |
| Mar 2026 | $995.8M | 0.16% |
| Dec 2025 | $994.2M | (1.06%) |
| Sep 2025 | $1.0B | (2.64%) |
| 42 more quarters | Free account |
Against its own ten years
Low $1.4B
High $4.1B
Ten-year median
$2.9B
Current reading's percentile
82
Revenue against peers
| Company | Revenue |
|---|---|
| LH Labcorp Holdings Inc. compare | $14.3B |
| DGX Quest Diagnostics Incorporated compare | $11.6B |
| ICLR ICON PLC compare | $8.3B |
| CRL Charles River Laboratories International, Inc. | $4.0B |
| RVTY Revvity Inc. compare | $2.9B |
| MEDP Medpace Holdings, Inc. compare | $2.8B |
| QGEN QIAGEN N.V. compare | $2.1B |
| GH Guardant Health, Inc. compare | $1.2B |
| TWST Twist Bioscience Corporation compare | $431.8M |
What Revenue is
Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.
Reported line item
More on CRL
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement